The best indicator for Pfizer (PFE)
We backtested 382 indicators across daily, weekly and hourly charts on real Pfizer (PFE) history. Here's what actually worked — risk-adjusted over the full backtest, with costs, and checked out-of-sample.
Where Pfizer (PFE) stands
Computed from our own daily OHLCV history, not quoted from a third party. Moving averages use closing prices; "52-week" is the last 252 trading sessions.
SMC: Change of Character
On the weekly chart, this is the strongest risk-adjusted edge we found for Pfizer (PFE) over ~54.5 years — trailing buy-and-hold by 0.2% CAGR.
Pfizer (PFE) on the weekly chart
The timeframe our backtest found best for this asset. The chart is live market data; the results above are hypothetical and historical.
Chart by TradingView. Loading it contacts tradingview.com, which may set its own cookies — see our privacy policy.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for Pfizer (PFE) — trailing buy-and-hold by 4.6% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | SMC: Change of Character ✓ | Weekly | 10.0% | 0.57 | -44.2% | 60.0% | 25 | -0.2% |
| 2 | Volume Flow Indicator ✓ | Weekly | 9.9% | 0.56 | -47.6% | 58.8% | 17 | -0.3% |
| 3 | Positive Volume Index ✓ | Weekly | 9.6% | 0.55 | -50.3% | 56.2% | 16 | -0.7% |
| 4 | CCI (200) ✓ | Weekly | 9.7% | 0.55 | -54.1% | 40.0% | 25 | -0.6% |
| 5 | Trend Intensity Index ✓ | Weekly | 9.3% | 0.54 | -51.6% | 62.5% | 16 | -1.0% |
| 6 | Fibonacci Pivots ✓ | Weekly | 7.6% | 0.53 | -45.3% | 55.1% | 430 | -2.6% |
| 7 | EMA 200 Trend ✓ | Weekly | 9.4% | 0.53 | -49.4% | 43.2% | 37 | -0.8% |
| 8 | T3 10/40 Cross ✓ | Weekly | 8.5% | 0.53 | -52.2% | 53.8% | 26 | -1.7% |
| 9 | SMA 200 Trend ✓ | Weekly | 8.9% | 0.52 | -48.0% | 44.0% | 25 | -1.4% |
| 10 | SMA 20/80 Cross ✓ | Weekly | 8.6% | 0.52 | -49.3% | 57.9% | 19 | -1.6% |
| 11 | T3 15/60 Cross ✓ | Weekly | 8.1% | 0.51 | -53.2% | 61.1% | 18 | -2.2% |
| 12 | Pivot Points (Standard) ✓ | Weekly | 6.9% | 0.5 | -49.2% | 53.3% | 390 | -3.4% |
| 13 | TRIMA 200 Trend ✓ | Weekly | 8.5% | 0.5 | -50.2% | 39.1% | 23 | -1.8% |
| 14 | Intraday Momentum Index ✓ | Daily | 8.0% | 0.49 | -52.5% | 69.8% | 159 | -2.3% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
What it would take to beat buy & hold on Pfizer (PFE)
2 of 719 tested setups beat buy-and-hold on Pfizer (PFE) outright. Another 144 could get there with leverage they would survive — but 412 would be liquidated by their own drawdown before they caught it.
| Indicator | Beats B&H unlevered | Leverage needed | Leverage survived |
|---|---|---|---|
| Murrey Math Lines | 1 | none needed | 3.09× |
| Trade Volume Index | 1 | none needed | 1.74× |
| Volatility Stop (ATR) | — | 1.39× | 2.69× |
| Bollinger Mean-Reversion | — | 1.65× | 3.55× |
| Fibonacci Bands | — | 1.65× | 3.55× |
| Order-Flow Reversion | — | 1.69× | 4.33× |
Out-of-sample, costs included. A setup is only listed if the leverage it needs is less than the leverage its own worst drawdown survives — when it isn't, no amount of leverage gets there. Volatility drag isn't modelled, so these are the optimistic case. Every indicator, ranked this way
For Pfizer (PFE), SMC: Change of Character on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get alerted when Pfizer’s signal flips
We track Pfizer daily. Its backtested best indicator, SMC: Change of Character (Weekly), is long right now — we'll email you the moment that changes. Free, no spam, unsubscribe any time.